ZBH Valuation Metrics
ZBH Stock Price Metrics
ZBH Dividend Metrics
ZBH Growth Rate Metrics
ZBH Discounted Cash Flow Metrics
| Fair Value Price | $490.79 |
| Margin of Safety | 457.91% |
ZBH Revenue Metrics
ZBH PE Ratio Metrics
| PE Ratio | 22.85 |
| PE Ratio Avg TTM | 23.48 |
| PE Ratio Avg 3Y | 23.11 |
| Current VS TTM Avg | -2.67% |
| Current VS 3Y Avg | -1.12% |
| Current VS 5Y Avg | -51.61% |
ZBH PS Ratio Metrics
| PS Ratio | 2.05 |
| PS Ratio Avg TTM | 2.31 |
| PS Ratio Avg 3Y | 2.88 |
| Current VS TTM Avg | -11.43% |
| Current VS 3Y Avg | -28.81% |
| Current VS 5Y Avg | -36.17% |
ZBH PB Ratio Metrics
| PB Ratio | 1.36 |
| PB Ratio Avg TTM | 1.47 |
| PB Ratio Avg 3Y | 1.74 |
| Current VS TTM Avg | -7.36% |
| Current VS 3Y Avg | -21.79% |
| Current VS 5Y Avg | -28.53% |
ZBH Price to Free Cash Flow Ratio Metrics
| PFCF Ratio | 9.38 |
| PFCF Ratio Avg TTM | 11.78 |
| PFCF Ratio Avg 3Y | 18.40 |
| Current VS TTM Avg | -20.35% |
| Current VS 3Y Avg | -49.01% |
| Current VS 5Y Avg | -52.24% |
ZBH Debt to Equity Ratio Metrics
| Debt/Equity Ratio | 0.59 |
| Debt/Equity Ratio Avg TTM | 0.54 |
| Debt/Equity Ratio Avg 3Y | 0.51 |
| Current VS TTM Avg | +8.26% |
| Current VS 3Y Avg | +16.83% |
| Current VS 5Y Avg | +8.92% |
ZBH PEG Ratio Metrics
| PEG Ratio | - |
| PEG Ratio Avg TTM | - |
| PEG Ratio Avg 3Y | 1.03 |
| Current VS TTM Avg | - |
| Current VS 3Y Avg | - |
| Current VS 5Y Avg | - |
ZBH FCF Yield
| FCF Yield | 10.66% |
| FCF Yield Avg TTM | 8.74% |
| FCF Yield Avg 3Y | 6.10% |
| Current VS TTM Avg | +22.01% |
| Current VS 3Y Avg | +74.77% |
| Current VS 5Y Avg | +116.89% |
ZBH Earnings Yield
| Earnings Yield | 4.38% |
| Earnings Yield Avg TTM | 4.29% |
| Earnings Yield Avg 3Y | 4.36% |
| Current VS TTM Avg | +2.07% |
| Current VS 3Y Avg | +0.40% |
| Current VS 5Y Avg | +47.25% |
ZBH EV/EBIT Ratio Metrics
| Ev/Ebit Ratio | 18.50 |
| Ev/Ebit Ratio Avg TTM | 19.67 |
| Ev/Ebit Ratio Avg 3Y | 21.59 |
| Current VS TTM Avg | -5.95% |
| Current VS 3Y Avg | -14.30% |
| Current VS 5Y Avg | -37.74% |
ZBH EV/EBITDA Ratio Metrics
| Ev/Ebitda Ratio | 11.00 |
| Ev/Ebitda Ratio Avg TTM | 11.08 |
| Ev/Ebitda Ratio Avg 3Y | 12.87 |
| Current VS TTM Avg | -0.73% |
| Current VS 3Y Avg | -14.50% |
| Current VS 5Y Avg | -30.13% |
ZBH EV/Assets Ratio Metrics
| Ev/Assets Ratio | 1.07 |
| Ev/Assets Ratio Avg TTM | 1.10 |
| Ev/Assets Ratio Avg 3Y | 1.27 |
| Current VS TTM Avg | -2.90% |
| Current VS 3Y Avg | -15.51% |
| Current VS 5Y Avg | -19.97% |
ZBH EV/Sales Ratio Metrics
| Ev/Sales Ratio | 2.89 |
| Ev/Sales Ratio Avg TTM | 3.16 |
| Ev/Sales Ratio Avg 3Y | 3.65 |
| Current VS TTM Avg | -8.54% |
| Current VS 3Y Avg | -20.92% |
| Current VS 5Y Avg | -27.56% |
ZBH Current Ratio Metrics
| Current Ratio | 1.98 |
| Current Ratio Avg TTM | 1.94 |
| Current Ratio Avg 3Y | 1.85 |
| Current VS TTM Avg | +1.80% |
| Current VS 3Y Avg | +7.32% |
| Current VS 5Y Avg | +10.20% |
ZBH Quick Ratio Metrics
| Quick Ratio | 1.10 |
| Quick Ratio Avg TTM | 1.04 |
| Quick Ratio Avg 3Y | 0.96 |
| Current VS TTM Avg | +5.26% |
| Current VS 3Y Avg | +14.58% |
| Current VS 5Y Avg | +16.61% |
ZBH ROIC Metrics
| ROIC | 5.48% |
| ROIC Avg 3Y | 5.01% |
| ROIC Avg 5Y | 3.94% |
| Current VS 3Y Avg | +9.33% |
| Current VS 5Y Avg | +39.09% |
| Current VS 10Y Avg | +65.79% |
ZBH Return on Assets Metrics
| ROA | 3.05 |
| ROA Avg TTM | 3.64 |
| ROA Avg 3Y | 3.29 |
| Current VS TTM Avg | -16.21% |
| Current VS 3Y Avg | -7.15% |
| Current VS 5Y Avg | +28.15% |
ZBH Return on Equity Metrics
| ROE | 5.55 |
| ROE Avg TTM | 6.40 |
| ROE Avg 3Y | 5.73 |
| Current VS TTM Avg | -13.28% |
| Current VS 3Y Avg | -3.18% |
| Current VS 5Y Avg | +33.41% |
ZBH Net Profit Margin Metrics
| Net Profit Margin | 8.57% |
| Net Profit Margin Avg TTM | 10.17% |
| Net Profit Margin Avg 3Y | 9.38% |
| Current VS TTM Avg | -15.73% |
| Current VS 3Y Avg | -8.64% |
| Current VS 5Y Avg | +25.02% |
Last Updated: Saturday, June 20, 2026
About Zimmer Biomet Holdings, Inc.
Zimmer Biomet Holdings, Inc. (ZBH), along with its global subsidiaries, operates as a leading player in the musculoskeletal healthcare sector. The company extends its reach across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. ZBH is responsible for the design, manufacturing, and marketing of a wide array of orthopedic reconstructive solutions, including prominent knee and hip replacement systems. Their offerings also encompass Specialized Enabling Technologies (S.E.T.) products, which cover areas such as sports medicine, biologics, foot and ankle care, extremity treatments, and trauma management. Furthermore, the company provides medical devices and surgical instruments specifically for spinal conditions, alongside products for facial and cranial reconstruction. A unique part of their portfolio includes systems designed to stabilize and fixate chest bones, facilitating recovery or reconstruction following open-heart surgery, traumatic injuries, or congenital chest deformities. The company's product lines also feature a comprehensive range of dental solutions, such as reconstructive implants, prosthetics, and regenerative materials. Additionally, they are involved in robotic surgical systems, general surgical instruments, and bone cements. These advanced products and solutions are primarily utilized to address conditions in patients suffering from disorders or injuries affecting bones, joints, and their associated soft tissues. Zimmer Biomet caters to a broad clientele, including orthopedic, neuro-, and oral surgeons, dentists, hospitals, independent distributors, healthcare suppliers, and various other medical specialists. Their network further encompasses agents, healthcare purchasing organizations, and group buying alliances. Originally established in 1927, the enterprise was initially known as Zimmer Holdings, Inc., before rebranding as Zimmer Biomet Holdings, Inc. in June 2015. Its corporate headquarters are situated in Warsaw, Indiana.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ivan Tornos